Certain Restricted Stock Units of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024.
February 17, 2024
Share
Certain Restricted Stock Units of Voyager Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-FEB-2024. These Restricted Stock Units will be under lockup for 45 days starting from 4-JAN-2024 to 18-FEB-2024.
Details:
The Company's officers and directors have agreed that they may not offer, sell, assign, transfer, pledge, contract to sell, lend, or otherwise dispose of, or announce the intention to otherwise dispose of any shares of common stock without the prior written consent of Citigroup Global Markets Inc. and Guggenheim Securities, LLC (which consent may be withheld at the sole discretion of Citigroup Global Markets Inc. or Guggenheim Securities, LLC), directly or indirectly for a period of 45 days from the date of this prospectus supplement.
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Companyâs pipeline includes programs for Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Parkinsonâs disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreichâs Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimerâs disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
VOYAGER THERAPEUTICS, INC. 
